TISSUE ACYLATION BY THE CHLOROFLUOROCARBON SUBSTITUTE 2,2-DICHLORO-1,1,1-TRIFLUOROETHANE

被引:61
作者
HARRIS, JW
POHL, LR
MARTIN, JL
ANDERS, MW
机构
[1] UNIV ROCHESTER,DEPT PHARMACOL,ROCHESTER,NY 14642
[2] NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892
[3] JOHNS HOPKINS MED INST,DEPT ANESTHESIOL & CRIT CARE MED,BALTIMORE,MD 21205
关键词
HEPATIC METABOLISM; HYDROCHLOROFLUOROCARBONS; TRIFLUOROACETYLATED PROTEINS; NEOANTIGENS; F-19; NMR;
D O I
10.1073/pnas.88.4.1407
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hydrochlorofluorocarbons (HCFCs) are being developed as substitutes for ozone-depleting chlorofluorocarbons (CFCs); because widespread human exposure to HCFCs may be expected, it is important to evaluate their toxicities thoroughly. Here we report studies on the bioactivation of the CFC substitute 2,2-dichloro-1,1,1-trifluorethane (HCFC-123) to an electrophilic intermediate that reacts covalently with liver proteins. HCFC-123 and its analog halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) were studied in rats by F-19 NMR spectroscopy, and we found that a trifluoroacetylated lysine adduct was formed with liver proteins. Also, the pattern of proteins immunoreactive with hapten-specific anti-trifluoroacetylprotein antibodies was identical in livers of HCFC-123- and halothane-exposed rats. Because halothane causes an idiosyncratic, and sometimes fatal, hepatitis that is associated with an immune response against several trifluoroacetylated liver proteins, the present findings raise the possibility that humans exposed to HCFC-123 or structurally related HCFCs may be at risk of developing an immunologically mediated hepatitis.
引用
收藏
页码:1407 / 1410
页数:4
相关论文
共 30 条
[1]  
Anders M. W., 1985, BIOACTIVATION FOREIG, P284
[2]  
ANDERS MW, 1990, IN PRESS ENV HLTH PE
[3]   ENFLURANE METABOLISM PRODUCES COVALENTLY BOUND LIVER ADDUCTS RECOGNIZED BY ANTIBODIES FROM PATIENTS WITH HALOTHANE HEPATITIS [J].
CHRIST, DD ;
KENNA, JG ;
KAMMERER, W ;
SATOH, H ;
POHL, LR .
ANESTHESIOLOGY, 1988, 69 (06) :833-838
[4]  
ELKINS CL, 1989, EPA OPTS10008
[5]   MODEL-CALCULATIONS OF THE RELATIVE EFFECTS OF CFCS AND THEIR REPLACEMENTS ON STRATOSPHERIC OZONE [J].
FISHER, DA ;
HALES, CH ;
FILKIN, DL ;
KO, MKW ;
SZE, ND ;
CONNELL, PS ;
WUEBBLES, DJ ;
ISAKSEN, ISA ;
STORDAL, F .
NATURE, 1990, 344 (6266) :508-512
[6]  
GANDOLFI AJ, 1980, J PHARMACOL EXP THER, V214, P721
[7]  
GUNTHER H, 1987, NMR SPECTROSCOPY, P343
[8]  
JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P508
[9]  
KENNA JG, 1988, J PHARMACOL EXP THER, V245, P1103
[10]  
KENNA JG, 1987, J PHARMACOL EXP THER, V242, P733